推荐产品
等級
pharmaceutical primary standard
API 家族
mirtazapine
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
SMILES 字串
CN1CCN2C(C1)c3ccccc3Cc4cccnc24
InChI
1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
InChI 密鑰
RONZAEMNMFQXRA-UHFFFAOYSA-N
基因資訊
human ... ADRA2A(150) , ADRA2B(151) , ADRA2C(152) , HTR2A(3356) , HTR2C(3358)
正在寻找类似产品? 访问 产品对比指南
相关类别
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Mirtazapine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化／生理作用
Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). Mirtazapine agonizes selective adrenergic and serotonergic receptors so that both NE release and 5-HT1A mediated serotonergic signaling are increased.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral - STOT SE 3
標靶器官
Central nervous system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Hun Soo Chang et al.
Journal of neural transmission (Vienna, Austria : 1996), 122(1), 59-68 (2014-12-03)
Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is among the most consistent neuroendocrine abnormalities in major depressive disorder (MDD). The peptide adrenocorticotropin hormone (ACTH) mediates HPA axis function during stress and is encoded by the proopiomelanocortin (POMC) gene polycistronically. After screening
Katarzyna Kamińska et al.
Pharmacological reports : PR, 66(6), 984-990 (2014-12-03)
The aim of our study was to understand the mechanism of clinical efficacy of the combination of an antidepressant and risperidone in drug-resistant depression. We studied the effect of an antidepressant (mirtazapine) and risperidone (atypical antipsychotic), given separately or jointly
Andrea de Bejczy et al.
Journal of clinical psychopharmacology, 35(1), 43-50 (2014-12-18)
The number of therapeutic drugs available for the treatment of alcohol use disorders (AUDs) is limited, and a well-tolerated, self-administrable drug is much needed. Subgroups of alcohol-dependent individuals, for example, individuals with heredity for AUD, may respond differently to pharmacological
Michael Paulzen et al.
Psychopharmacology, 232(4), 807-813 (2014-08-26)
The aim of this study was to investigate the distribution pattern of mirtazapine and its metabolite normirtazapine (N-desmethylmirtazapine) in blood and cerebrospinal fluid (CSF). Concentrations of mirtazapine were measured in blood serum and CSF of 16 patients treated with daily
Jui-Hsiu Tsai et al.
International journal of molecular sciences, 15(8), 13223-13235 (2014-07-30)
Major depressive disorder and cardiovascular disease are common serious illnesses worldwide. Selective serotonin reuptake inhibitors and norepinephrine-dopamine reuptake inhibitors may reduce the mortality of cardiovascular disease patients with comorbid depression. Interferon-γ-inducible protein 10 (IP-10), a type 1 T helper cell
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门